-
Xeljanz Safety Study Final Data Details the Increased Risks of Cancers and Major Adverse Cardiovascular Events
January 2022 Medical Journal Article Presents Full Set of Findings for the Xeljanz "ORAL Surveillance" Trial Which Started in 2014 (Posted by Tom Lamb at Drug Injury Watch) One year ago Pfizer released some preliminary…
-
Beovu Drug Label Change in December 2021 Adds More Information About Vision Loss Side Effects
Provides "risk factors and possible mechanism" for Beovu-related Retinal Vasculitis and Retinal Vascular Occlusion (Posted by Tom Lamb at Drug Injury Watch) Update: "Novartis Finally Issues Revised Beovu Prescribing Information for US in February 2022"…
-
Beovu Safety Developments Presented by JAMA Ophthalmology Medical Journal in November 2021
Meanwhile, Still Waiting for the Anticipated Beovu Label Change That Was Previewed by Novartis Back in May 2021 (Posted by Tom Lamb at Drug Injury Watch) As the year 2021 draws to an end, we…
-
December 2021 JAK Inhibitors Drug Class Label Changes: More Warnings and Use Restrictions
Risks of Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq (Posted by Tom Lamb at Drug Injury Watch) As background, in September 2021 the FDA announced that it was requiring…
